Company intelligence / Profile preview

Chugai Venture Fund

Boston, Massachusetts, United Stateschugaiventurefund.com ↗

Ownership: Private
Development stage: Other

Overview

Chugai Venture Fund began full-scale operations in early 2024 with a $200M fund to invest globally—primarily US/EU/Japan—in innovative drug discovery start-ups. Its first investments include Leal Therapeutics (precision CNS medicines), Hyku Biosciences (novel small molecules), and Stylus Medicine (in vivo genetic medicines). The fund aims to accelerate the development of breakthrough therapies by providing strategic funding and leveraging the expertise of its parent company.

Therapeutic areas: OncologyRare DiseasesImmunologyOphthalmologyNeurology
Modalities: Small moleculeMonoclonal antibodyGene therapyPlatform technologies
Industry: Investors

Partnerships

Portfolio partnerships with Leal TherapeuticsHyku BiosciencesStylus Medicine

Beyond the preview

Go deeper on Chugai Venture Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chugai Venture Fund.

Explore the full profile